A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
An open-label, dose escalation and expansion clinical trial to evaluate the safety,
tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic
colorectal cancer and metastatic breast cancer.